Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 2-Picolinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.50 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.47 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.47 |
| ▸ | KCNK3 known ✓ | O14649 | 1/20 | 0.47 |
| ▸ | KCNK9 known ✓ | Q9NPC2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.95 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.95 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.95 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.95 |
| ▸ | CES2 | O00748 | 1/20 | 0.67 |
| ▸ | CES1 | P23141 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Picolinic Acid SCHEMBL30779159 | 1.00 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL29761294 | 1.00 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL1469 | 1.00 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL890376 | 1.00 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL28128752 | 1.00 | LMNA (0.95) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL2164674 | 0.98 | LMNA (0.91) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL22288254 | 0.98 | LMNA (0.91) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL28256814 | 0.98 | LMNA (0.91) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL674837 | 0.98 | LMNA (1.00) | LMNAL3MBTL1NAPRTP4HTMCES2 | |
| 2-Picolinic Acid SCHEMBL29368665 | 0.98 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1602648-B2 | Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same | IDEMITSU KOSAN CO (JP) | 2025-03-26 | — | — | EP | disclosed |
| CN-115427027-B | Agent for improving mitochondrial dysfunction | 滨特劳工公司 | 2024-12-10 | — | — | CN | disclosed |
| US-11814338-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | REATA PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-112703037-B | 5-to 7-membered heterocyclic amides as JAK inhibitors | 施万生物制药研发IP有限责任公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-112739697-B | Dimethylaminoazetidine amides as JAK inhibitors | 施万生物制药研发IP有限责任公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116751157-A | Amplified preparation method of 2- (2-amino-5-bromo-benzoyl) pyridine | 上海再启生物技术有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-115427027-A | Mitochondrial dysfunction ameliorating agent | 滨特劳工公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-115190878-A | Crystalline hydrates of JAK inhibitor compounds | 施万生物制药研发IP有限责任公司 | 2022-10-14 | — | — | CN | disclosed |
| US-20220281807-A1 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-11192852-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | REATA PHARMACEUTICALS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-4950762-A | ANTIULCER AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-08-21 | — | — | US | disclosed |
| US-4886821-A | 2-pyridinecarbothioamides and pharmaceutical compositions comprising the same useful as anti ulcer agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-12-12 | — | — | US | disclosed |
| US-4873238-A | ANTIULCER AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-10-10 | — | — | US | disclosed |
| US-4698430-A | ANTIDEPRESSANT | A. H. ROBINS COMPANY, INC. (US) | 1987-10-06 | — | — | US | disclosed |
| EP-0074628-B1 | ASCOCHLORIN DERIVATIVES; PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 1986-05-28 | — | — | EP | disclosed |
| US-4558132-A | ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-12-10 | — | — | US | disclosed |
| US-4542143-A | DIABETES, ANTITUMOR, LIPID METABOLISM | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1985-09-17 | — | — | US | disclosed |
| US-4500544-A | ANTIDIABETIC AGENTS; ANTITUMOR AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1985-02-19 | — | — | US | disclosed |
| EP-0099614-A2 | Nitro, amino and aroylamino-N-phenylpyridinamines and their use in a process for preparing pyrido(1,4)benzodiazapines | A.H. ROBINS COMPANY, INCORPORATED (US) | 1984-02-01 | — | — | EP | disclosed |
| EP-0074628-A2 | Ascochlorin derivatives; process for preparing the same and pharmaceutical composition containing the same | Chugai Seiyaku Kabushiki Kaisha (JP) | 1983-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281807-A1 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | GPX4, MPO, GPX1 | PTGS2 31/4885OPRK1 549/4885AGTR1 1736/4885 |
| US-11192852-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | GPX4, MPO, GPX1 | PTGS2 31/4885OPRK1 549/4885AGTR1 1736/4885 |
| US-11814338-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | GPX4, MPO, GPX1 | PTGS2 31/4885OPRK1 549/4885AGTR1 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.